| Overall n=268 | Cluster 1 n=158 | Cluster 2 n=36 | Cluster 3 n=74 | p-value | |
|---|---|---|---|---|---|
| Most represented age group (%) | 41-50 (32%) | 41-50 (41%) | 31-40 (42%) | 51-60 (39%) | < 0.001 |
| Comorbidities 0 / ≥ 4 | 20% / 37% | 30% / 4% | 14% / 8% | 3% / 36% | < 0.001 |
| Ability to identify coming flare | 82% | 73% | 97% | 93% | < 0.001 |
| Current lupus control (no or poor) | 26% | 20% | 25% | 38% | < 0.05 |
| Current galenic (inj. / oral) | 12% / 76% | 2% / 83% | 8% / 78% | 35% / 61% | < 0.001 |
| Trial participation | 7% | 0% | 50% | 1% | < 0.001 |
| Ideal galenic oral | 62% | 84% | 50% | 20% | < 0.001 |
| implant | 19% | 9% | 33% | 32% | |
| home / auto-inj. | 14% / 9% | 6% / 2% | 11% / 11% | 32% / 22% | |
| hospital inj. | 6% | 1% | 5% | 15% | |
| Top ranked drug characteristics$ (%) | Side effects (32%) | Side effects (41%) | Pregnancy (55%) | Cortisone sparing (24%) | < 0.001 |
$among the 10 following items: less side effects, compatibility with pregnancy, better long term tolerance, less costly for collectivity, more convenient place for administration, easier administration, less medical follow-up needed, less risk of infection, cortisone sparing effect, shorter time of administration. P-values obtained after χ2 tests. Inj.: injection.